Ascentage Pharma’s Olverembatinib Joins China’s Reimbursement List

Ascentage Pharma Group International (HK:6855) has released an update.

Ascentage Pharma’s novel drug, olverembatinib, has been added to China’s 2024 National Reimbursement Drug List, enhancing its accessibility for patients with chronic myeloid leukemia (CML). This inclusion is expected to broaden the reach of olverembatinib, a first third-generation BCR-ABL inhibitor approved in China, addressing resistance challenges in CML treatment. The drug is being jointly commercialized by Ascentage Pharma and Innovent Biologics.

For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.